|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA A Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
|
|
2
|
Lu C, Shan Z, Hong J and Yang L:
MicroRNA-92a promotes epithelial-mesenchymal transition through
activation of PTEN/PI3K/AKT signaling pathway in non-small cell
lung cancer metastasis. Int J Oncol. 51:235–244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Armas-Lopez L, Piña-Sánchez P, Arrieta O,
de Alba EG, Ortiz-Quintero B, Santillán-Doherty P, Christiani DC,
Zúñiga J and Ávila-Moreno F: Epigenomic study identifies a novel
mesenchyme homeobox2-GLI1 transcription axis involved in cancer
drug resistance, overall survival and therapy prognosis in lung
cancer patients. Oncotarget. 8:67056–67081. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bai M, Li W, Yu N, Zhang H, Long F and
Zeng A: The crosstalk between β-catenin signaling and type I, type
II and type III interferons in lung cancer cells. Am J Transl Res.
9:2788–2797. 2017.PubMed/NCBI
|
|
5
|
Hu T and Lu YR: BCYRN1, a c-MYC-activated
long non-coding RNA, regulates cell metastasis of non-small-cell
lung cancer. Cancer Cell Int. 15:362015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pang L, Han S, Jiao Y, Jiang S, He X and
Li P: Bu Fei Decoction attenuates the tumor associated macrophage
stimulated proliferation, migration, invasion and immunosuppression
of non-small cell lung cancer, partially via IL-10 and PD-L1
regulation. Int J Oncol. 51:25–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Romero-Cordoba SL, Salido-Guadarrama I,
Rodriguez-Dorantes M and Hidalgo-Miranda A: miRNA biogenesis:
Biological impact in the development of cancer. Cancer Biol Ther.
15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naidu S, Magee P and Garofalo M:
miRNA-based therapeutic intervention of cancer. J Hematol Oncol.
8:682015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganju A, Khan S, Hafeez BB, Behrman SW,
Yallapu MM, Chauhan SC and Jaggi M: miRNA nanotherapeutics for
cancer. Drug Discov Today. 22:424–432. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mishra S, Yadav T and Rani V: Exploring
miRNA based approaches in cancer diagnostics and therapeutics. Crit
Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao C, Lu F and Chen H, Zhao F, Zhu Z,
Zhao X and Chen H: Clinical significance of circulating miRNA
detection in lung cancer. Med Oncol. 33:412016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang C, Hu X, Alattar M and Zhao H: miRNA
expression profiles associated with diagnosis and prognosis in lung
cancer. Expert Rev Anticancer Ther. 14:453–461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin CH, Tsai CH, Yeh CT, Liang JL, Hung
WC, Lin FC, Chang WL, Li HY, Yao YC, Hsu TI, et al:
miR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response
indicator of esophageal squamous cell carcinoma. Oncotarget.
7:39680–39693. 2016.PubMed/NCBI
|
|
15
|
Zhou J, Duan H, Xie Y, Ning Y, Zhang X,
Hui N, Wang C, Zhang J and Zhou J: miR-193a-5p targets the coding
region of AP-2a mRNA and induces cisplatin resistance in bladder
cancers. J Cancer. 7:1740–1746. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jacques C, Calleja LR, Baud'huin M,
Quillard T, Heymann D, Lamoureux F and Ory B: miRNA-193a-5p
repression of p73 controls Cisplatin chemoresistance in primary
bone tumors. Oncotarget. 7:54503–54514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pu Y, Zhao F, Cai W, Meng X, Li Y and Cai
S: miR-193a-3p and miR-193a-5p suppress the metastasis of human
osteosarcoma cells by down-regulating Rab27B and SRR, respectively.
Clin Exp Metastasis. 33:359–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang P, Ji DB, Han HB, Shi YF, Du CZ and
Gu J: Downregulation of miR-193a-5p correlates with lymph node
metastasis and poor prognosis in colorectal cancer. World J
Gastroenterol. 20:12241–12248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Y, Zhou L, Lu L, Wang L, Li X, Jiang
P, Chan LK, Zhang T, Yu J, Kwong J, et al: A novel
miR-193a-5p-YY1-APC regulatory axis in human endometrioid
endometrial adenocarcinoma. Oncogene. 32:3432–3442. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toren P and Zoubeidi A: Targeting the
PI3K/Akt pathway in prostate cancer: Challenges and opportunities
(review). Int J Oncol. 45:1793–1801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Georgi B, Korzeniewski N, Hadaschik B,
Grüllich C, Roth W, Sültmann H, Pahernik S, Hohenfellner M and
Duensing S: Evolving therapeutic concepts in prostate cancer based
on genome-wide analyses (review). Int J Oncol. 45:1337–1344. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie Y, Naizabekov S, Chen Z and Tokay T:
Power of PTEN/AKT: Molecular switch between tumor suppressors and
oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Steelman LS, Martelli AM, Cocco L, Libra
M, Nicoletti F, Abrams SL and McCubrey JA: The therapeutic
potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol.
82:1189–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicoletti F, Fagone P, Meroni P, McCubrey
J and Bendtzen K: mTOR as a multifunctional therapeutic target in
HIV infection. Drug Discov Today. 16:715–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Gao S, Wang C, Wang Z, Zhang H,
Huang K, Zhou B, Li H, Yu Z, Wu J and Chen C: Pathologically
decreased expression of miR-193a contributes to metastasis by
targeting WT1-E-cadherin axis in non-small cell lung cancers. J Exp
Clin Cancer Res. 35:1732016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tomczak K, Czerwinska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
32
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thul PJ, Akesson L, Wiking M, Mahdessian
D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM,
et al: A subcellular map of the human proteome. Science.
356:eaal33212017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Keller A, Leidinger P, Borries A,
Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP and
Meese E: miRNAs in lung cancer - studying complex fingerprints in
patient's blood cells by microarray experiments. BMC cancer.
9:3532009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patnaik SK, Yendamuri S, Kannisto E,
Kucharczuk JC, Singhal S and Vachani A: MicroRNA expression
profiles of whole blood in lung adenocarcinoma. PloS One.
7:e460452012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Keller A, Leidinger P, Bauer A, Elsharawy
A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al:
Toward the blood-borne miRNome of human diseases. Nat Methods.
8:841–843. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Patnaik SK, Kannisto ED, Mallick R,
Vachani A and Yendamuri S: Whole blood microRNA expression may not
be useful for screening non-small cell lung cancer. PloS One.
12:e01819262017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Keller A, Leidinger P, Vogel B, Backes C,
ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick
R, et al: miRNAs can be generally associated with human pathologies
as exemplified for miR-144. BMC Med. 12:2242014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46729January
8–2017
|
|
41
|
Leidinger P, Galata V, Backes C, Stähler
C, Rheinheimer S, Huwer H, Meese E and Keller A: Longitudinal study
on circulating miRNAs in patients after lung cancer resection.
Oncotarget. 6:16674–16685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang
C, Wan J, Zhou F, Shao K, Sun Y, et al: A 5-microRNA signature for
lung squamous cell carcinoma diagnosis and hsa-miR-31 for
prognosis. Clin Cancer Res. 17:6802–6811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nymark P, Guled M, Borze I, Faisal A,
Lahti L, Salmenkivi K, Kettunen E, Anttila S and Knuutila S:
Integrative analysis of microRNA, mRNA and aCGH data reveals
asbestos- and histology-related changes in lung cancer. Genes
Chromosomes Cancer. 50:585–597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19945January
8–2017
|
|
45
|
Bjaanaes MM, Halvorsen AR, Solberg S,
Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M,
Pastorino U, Kure E, et al: Unique microRNA-profiles in
EGFR-mutated lung adenocarcinomas. Int J Cancer. 135:1812–1821.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Robles AI, Arai E, Mathé EA, Okayama H,
Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, et
al: An integrated prognostic classifier for stage I lung
adenocarcinoma based on mRNA, microRNA, and DNA methylation
Biomarkers. J Thorac Oncol. 10:1037–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gasparini P, Cascione L, Landi L, Carasi
S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, et
al: microRNA classifiers are powerful diagnostic/prognostic tools
in ALK-, EGFR-, and KRAS-driven lung cancers. Proc Natl Acad Sci
USA. 112:pp. 14924–14929. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
48
|
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74190January
8–2017
|
|
49
|
Yoshimoto TI, Motoi N, Yamamoto N, Nagano
H, Ushijima M, Matsuura M, Okumura S, Yamaguchi T, Fukayama M and
Ishikawa Y: Pulmonary carcinoids and low-grade gastrointestinal
neuroendocrine tumors show common microRNA expression profiles,
different from adenocarcinomas and small cell carcinomas.
Neuroendocrinology. 106:47–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Halvorsen AR, Silwal-Pandit L, Meza-Zepeda
LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale
AL, Brustugun OT and Helland Å: TP53 mutation spectrum in smokers
and never smoking lung cancer patients. Front Genet. 7:852016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mogi A and Kuwano H: TP53 mutations in
nonsmall cell lung cancer. J Biomed Biotechnol. 2011:5839292011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang L, Zhou JG, Yao WX, Tian X, Lv SP,
Zhang TY, Jin SH, Bai YJ and Ma H: Systematic review and
meta-analysis of the efficacy of serum neuron-specific enolase for
early small cell lung cancer screening. Oncotarget. 8:64358–64372.
2017.PubMed/NCBI
|
|
53
|
Isgro MA, Bottoni P and Scatena R:
Neuron-specific enolase as a biomarker: Biochemical and clinical
aspects. Adv Exp Med Biol. 867:125–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zou Y, Wang L, Zhao C, Hu Y, Xu S, Ying K,
Wang P and Chen X: CEA, SCC and NSE levels in exhaled breath
condensate-possible markers for early detection of lung cancer. J
Breath Res. 7:0471012013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Grunnet M and Sorensen JB:
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung
Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang B, He YJ, Tian YX, Yang RN, Zhu YR
and Qiu H: Clinical utility of haptoglobin in combination with CEA,
NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pac J Cancer
Prev. 15:9611–9614. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Okamura K, Takayama K, Izumi M, Harada T,
Furuyama K and Nakanishi Y: Diagnostic value of CEA and CYFRA 21-1
tumor markers in primary lung cancer. Lung Cancer. 80:45–49. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li N, Wang Y, Liu X, Luo P, Jing W, Zhu M
and Tu J: Identification of circulating long noncoding RNA HOTAIR
as a novel biomarker for diagnosis and monitoring of non-small cell
lung cancer. Technol Cancer Res Treat. Jan 1–2017.(Epub ahead of
print). View Article : Google Scholar
|
|
59
|
Zhou Q, Huang SX, Zhang F, Li SJ, Liu C,
Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel
potential biomarker for diagnosis and therapy in patients with
non-small cell lung cancer. Cell Prolif. 50:2017.https://doi.org/10.1111/cpr.12394simple10.1111/cpr.12394
View Article : Google Scholar
|
|
60
|
Inamura K: Diagnostic and therapeutic
potential of MicroRNAs in lung cancer. Cancers. 9:E492017.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ricciuti B, Mencaroni C, Paglialunga L,
Paciullo F, Crinò L, Chiari R and Metro G: Long noncoding RNAs: New
insights into non-small cell lung cancer biology, diagnosis and
therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen J, Wang R, Zhang K and Chen LB: Long
non-coding RNAs in non-small cell lung cancer as biomarkers and
therapeutic targets. J Cell Mol Med. 18:2425–2436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pan YW, Zhou ZG, Wang M, Dong JQ, Du KP,
Li S, Liu YL, Lv PJ and Gao JB: Combination of IL-6, IL-10 and
MCP-1 with traditional serum tumor markers in lung cancer diagnosis
and prognosis. Genet Mol Res. 15:2016.https://doi.org/10.4238/gmr15048949simple10.4238/gmr15048949
View Article : Google Scholar
|
|
64
|
Wang WJ, Tao Z, Gu W and Sun LH: Clinical
observations on the association between diagnosis of lung cancer
and serum tumor markers in combination. Asian Pac J Cancer Prev.
14:4369–4371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA. 105:pp.
10513–10518. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Skog J, Wurdinger T, van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Valadi H, Ekstrom K, Bossios A, Sjostrand
M, Lee JJ and Lotvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Pigati L, Yaddanapudi SC, Iyengar R, Kim
DJ, Hearn SA, Danforth D, Hastings ML, Duelli DM, et al: Selective
release of microRNA species from normal and malignant mammary
epithelial cells. PLoS One. 5:e135152010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu
Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA
signatures identified in a genome-wide serum microRNA expression
profiling predict survival of non-small-cell lung cancer. J Clin
Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Farsinejad S, Gheisary Z, Ebrahimi Samani
S and Alizadeh AM: Mitochondrial targeted peptides for cancer
therapy. Tumour Biol. 36:5715–5725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fulda S, Galluzzi L and Kroemer G:
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov.
9:447–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lafanechere L, Courtay-Cahen C, Kawakami
T, Jacrot M, Rüdiger M, Wehland J, Job D and Margolis RL:
Suppression of tubulin tyrosine ligase during tumor growth. J Cell
Sci. 111:171–181. 1998.PubMed/NCBI
|
|
73
|
Wei S, Wang Y, Xu H and Kuang Y: Screening
of potential biomarkers for chemoresistant ovarian carcinoma with
miRNA expression profiling data by bioinformatics approach. Oncol
Lett. 10:2427–2431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chua MM, Ortega CE, Sheikh A, Lee M,
Abdul-Rassoul H, Hartshorn KL and Dominguez I: CK2 in cancer:
Cellular and biochemical mechanisms and potential therapeutic
target. Pharmaceuticals (Basel). 10:E182017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ortega CE, Seidner Y and Dominguez I:
Mining CK2 in cancer. PLoS One. 9:e1156092014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Abdel-Magid AF: Inhibition of CK2: An
attractive therapeutic target for cancer treatment. ACS Med Chem
Lett. 4:1131–1132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bae JS, Park SH, Jamiyandorj U, Kim KM,
Noh SJ, Kim JR, Park HJ, Kwon KS, Jung SH, Park HS, et al:
CK2α/CSNK2A1 phosphorylates SIRT6 and is involved in the
progression of breast carcinoma and predicts shorter survival of
diagnosed patients. Am J Pathol. 186:3297–3315. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Rabjerg M, Bjerregaard H, Halekoh U,
Jensen BL, Walter S and Marcussen N: Molecular characterization of
clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1
as promising novel prognostic markers. APMIS. 124:372–383. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kulbe H, Iorio F, Chakravarty P, Milagre
CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D,
et al: Integrated transcriptomic and proteomic analysis identifies
protein kinase CK2 as a key signaling node in an inflammatory
cytokine network in ovarian cancer cells. Oncotarget.
7:15648–15661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Srivastava R, Akthar S, Sharma R and
Mishra S: Identification of Ellagic acid analogues as potent
inhibitor of protein Kinase CK2: A chemopreventive role in oral
Cancer. Bioinformation. 11:21–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Chatterjee A, Chatterjee U and Ghosh MK:
Activation of protein kinase CK2 attenuates FOXO3a functioning in a
PML-dependent manner: Implications in human prostate cancer. Cell
Death Dis. 4:e5432013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Schneider CC, Kartarius S, Montenarh M,
Orzeszko A and Kazimierczuk Z: Modified tetrahalogenated
benzimidazoles with CK2 inhibitory activity are active against
human prostate cancer cells LNCaP in vitro. Bioorg Med Chem.
20:4390–4396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Nelson N, Szekeres K, Iclozan C, Rivera
IO, McGill A, Johnson G, Nwogu O and Ghansah T: Apigenin: Selective
CK2 inhibitor increases Ikaros expression and improves T cell
homeostasis and function in murine pancreatic cancer. PLoS One.
12:e01701972017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Benavent Acero F, Capobianco CS, Garona J,
Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF and
Farina HG: CIGB-300, an anti-CK2 peptide, inhibits angiogenesis,
tumor cell invasion and metastasis in lung cancer models. Lung
cancer. 107:14–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ku MJ, Park JW, Ryu BJ, Son YJ, Kim SH and
Lee SY: CK2 inhibitor CX4945 induces sequential inactivation of
proteins in the signaling pathways related with cell migration and
suppresses metastasis of A549 human lung cancer cells. Bioor Med
Chem Lett. 23:5609–5613. 2013. View Article : Google Scholar
|
|
86
|
Zhou Y, Li K, Zhang S, Li Q, Li Z, Zhou F,
Dong X, Liu L, Wu G and Meng R: Quinalizarin, a specific CK2
inhibitor, reduces cell viability and suppresses migration and
accelerates apoptosis in different human lung cancer cell lines.
Indian J Cancer. 52 Suppl 2:e119–e124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
So KS, Rho JK, Choi YJ, Kim SY, Choi CM,
Chun YJ and Lee JC: AKT/mTOR down-regulation by CX-4945, a CK2
inhibitor, promotes apoptosis in chemorefractory non-small cell
lung cancer cells. Anticancer Res. 35:1537–1542. 2015.PubMed/NCBI
|
